知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

51 records (took 0.027 seconds)

    Albumin-Fused Kunitz Domain Peptides
    2.
    发明申请
    Albumin-Fused Kunitz Domain Peptides 审中-公开
    白蛋白融合Kunitz结构域肽

    公开(公告)号：US20080274969A1

    公开(公告)日：2008-11-06

    申请号：US12114477

    申请日：2008-05-02

    Applicant: Hans-Peter Hauser ,  Thomas Weimer ,  Val Romberg ,  Scott M. Kee ,  Darrell Sleep ,  Robert Charles Ladner ,  Arthur C. Ley

    Inventor： Hans-Peter Hauser ,  Thomas Weimer ,  Val Romberg ,  Scott M. Kee ,  Darrell Sleep ,  Robert Charles Ladner ,  Arthur C. Ley

    IPC: A61K38/38 ,  C07K14/76 ,  C07H21/00 ,  C12N15/00 ,  C12N5/00 ,  C12P21/04

    CPC classification number: C12N15/62 ,  C07K2319/31

    Abstract: The invention relates to proteins comprising serine protease inhibiting peptides, such as Kunitz domain peptides (including, but not limited to, fragments and variants thereof) fused to albumin, or fragments or variants thereof. These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules and vectors encoding the albumin fusion proteins of the invention, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for inhibiting neutrophil elastase, kallikrein, and plasmin. The invention further relates to compositions and methods for treating cystic fibrosis and cancer.

    Abstract translation: 本发明涉及包含丝氨酸蛋白酶抑制肽的蛋白质，例如与白蛋白或其片段或变体融合的Kunitz结构域肽（包括但不限于其片段和变体）。 这些融合蛋白在本文中统称为“本发明的白蛋白融合蛋白”。 这些融合蛋白在溶液中表现出延长的保质期和/或延长或治疗活性。 本发明包括治疗性白蛋白融合蛋白，组合物，药物组合物，制剂和试剂盒。 本发明还包括编码本发明的白蛋白融合蛋白，用这些核酸和载体转化的宿主细胞的核酸分子和载体，以及使用这些核酸，载体和/或宿主制备本发明的白蛋白融合蛋白的方法 细胞。 本发明还涉及抑制嗜中性粒细胞弹性蛋白酶，激肽释放酶和纤溶酶的组合物和方法。 本发明还涉及治疗囊性纤维化和癌症的组合物和方法。

    Binding peptides for carcinoembryonic antigen (CEA)
    3.
    发明授权
    Binding peptides for carcinoembryonic antigen (CEA) 有权
    癌胚抗原（CEA）的结合肽

    公开(公告)号：US07438890B2

    公开(公告)日：2008-10-21

    申请号：US11045477

    申请日：2005-01-26

    Applicant: Isaac J. Rondon ,  Robert Charles Ladner

    Inventor： Isaac J. Rondon ,  Robert Charles Ladner

    IPC: A61K38/00 ,  A61K38/04 ,  A61K38/08 ,  A61K38/10 ,  A61K38/12 ,  A61K49/00 ,  A61K51/08 ,  C07K4/00 ,  C07K7/00 ,  C07K7/04 ,  C07K9/00 ,  C07K11/00

    CPC classification number: C07K7/06 ,  C07K7/08 ,  C07K14/705

    Abstract: The present invention provides binding moieties for CEA, which have a variety of uses wherever detecting, isolating or localizing CEA, and particularly CEA as opposed to cross-reactive antigens such as NCA, is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding CEA, which is overexpressed in adenocarcinomas of endodermally derived digestive system epithelia and fetal colon. Such polypeptides and disclosed derivatives are useful, e.g., as imaging agents for CEA-expressing tumors.

    Abstract translation: 本发明提供了用于CEA的结合部分，其具有各种用途，无论检测，分离或定位CEA，特别是与交叉反应性抗原（例如NCA）相反，CEA是有利的。 特别公开的是能够结合CEA的合成的，分离的多肽，其在内皮衍生的消化系统上皮细胞和胎儿结肠的腺癌中过表达。 这样的多肽和所公开的衍生物是有用的，例如作为表达CEA的肿瘤的显像剂。

    Engineering affinity ligands for macromolecules
    6.
    发明授权
    Engineering affinity ligands for macromolecules 失效
    大分子工程亲和配体

    公开(公告)号：US06326155B1

    公开(公告)日：2001-12-04

    申请号：US08821498

    申请日：1997-03-21

    Applicant: John Moore Maclennan ,  Robert Charles Ladner

    Inventor： John Moore Maclennan ,  Robert Charles Ladner

    IPC: G01N3353

    CPC classification number: C40B30/04 ,  G01N33/6803 ,  G01N33/6845

    Abstract: A method is disclosed for obtaining highly specific and tailored ligands suitable for purifying a particular product target or for eliminating particular target impurities in a feed stream. Engineered affinity ligands according to the invention will bind a target with high specificity at a preselected binding condition and release the target at a preselected elution condition. The ligands are isolated by contacting a target with a multiplicity of polypeptides derived through variegation of the structure of a candidate binding domain, the variants (or analogues) including polypeptides favoring binding to the target under desired binding conditions and release from the target under elution conditions, where the binding and elution conditions differ according to one or more parameters, such as pH, temperature, concentration of salt or volume % of an organic solvent.

    Abstract translation: 公开了用于获得适于纯化特定产品靶或用于消除进料流中的特定目标杂质的高度特异性和定制的配体的方法。 根据本发明的工程化亲和配体将在预选的结合条件下以高特异性结合靶，并以预选的洗脱条件释放靶。 通过使靶标与通过杂交候选结合结构域的结构衍生的多种多肽接触来分离配体，所述变体（或类似物）包括有利于在期望的结合条件下与靶结合并在洗脱条件下从靶释放的多肽 其中结合和洗脱条件根据一个或多个参数（例如pH，温度，盐的浓度或有机溶剂的体积％）而不同。

Patent Agency Ranking